Accrued Liabilities (Notes)

6 Months Ended

Jun. 30, 2024

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities and Other Long-Term Liabilities

    Accrued liabilities consist of the following (in thousands): 

	As of
	June 30, 2024		December 31, 2023
Salaries and benefits	$	69,914	$	52,250
Incentive compensation	42,037		37,992
Operating lease liability-ST	17,915		20,161
Accrued sales taxes	5,545		6,748
Restructuring accrual	9,924		3,568
Deferred revenue	33,791		31,640
Accrued other taxes	5,390		3,024
Accrued professional fees	3,418		2,803
Italy medical device payback provision	23,613		23,176
Legal accrual	1,704		1,874
Distribution fees	16,522		13,049
Warranties and returns	3,600		3,682
Field service corrective action(1)	32,411		30,281
Accrued freight	15,764		17,215
Foreign exchange contracts	1,473		2,590
Accrued audit fees	4,626		5,492
Defined benefit plan	2,735		2,575
Accrued interest	1,409		1,431
Other	7,960		8,664
	$	299,751	$	268,215

___________________________

(1)     Primarily includes field service corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical’s Oakdale, Minnesota Facility, see Note 18: Commitments and Contingencies for further detail.

Other long-term liabilities consist of the following (in thousands): 

	As of
	June 30, 2024		December 31, 2023
Operating lease liability-LT	$	52,179	$	52,972
Benefits	3,932		4,207
Accrued rent	732		841
Finance lease liability-LT	2,397		1,954
Deferred revenue	10,015		10,585
Field service corrective action(1)	18,118		26,056
Other	3,983		3,882
	$	91,356	$	100,497